简体中文 | 繁體中文 | English

Press Releases

2024-12-18 10:18 Biocodex Strengthens Supply Chain Resilience with Kinaxis
2024-12-18 10:11 Cedo Acquires Plasta Group
2024-12-18 09:10 Boomi Boosts Data Management Capabilities With Acquisition of Modern Data Integration Provider Rivery
2024-12-18 09:07 Newline Group Opens New Office in Hong Kong
2024-12-18 09:04 Hong Kong (HKG) to Taipei (TPE) is the World’s Busiest International Airline Route in 2024, Latest OAG Data Reveals
2024-12-17 19:16 Japan Fruit and Vegetables Export Promotion Council: Smile Japanese Fruits Gift Campaign
2024-12-17 16:21 Boyd Watterson Names Don Haisch as Global Chief Financial Officer
2024-12-17 16:18 SLB Announces Fourth-Quarter and Full-Year 2024 Results Conference Call
2024-12-17 16:15 GLAS Completes Its Acquisition of Singaporean Corporate, Trust and Funds Service Provider, WATIGA
2024-12-17 16:11 HistoSonics Edison® Histotripsy System Treats First Pancreatic Tumor Patients in GANNON Trial
2024-12-17 14:59 TuSimple Co-Founder and Largest Investor Issues Letter to Stockholders
2024-12-17 10:53 Humanetics Publishes Groundbreaking Data on the Growth of the Chinese Population
2024-12-17 10:39 SpaceRISE Signs Concession Contract to Deliver Europe’s IRIS2 Connectivity Network
2024-12-17 10:33 Novotech Named a Fierce CRO Award Winner in the Excellence in Clinical Trial Management and Global Operations Categories
2024-12-17 10:17 ONE Development Announces Strategic Collaboration with The Legend Amr Diab as Brand Ambassador
2024-12-17 10:10 Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development
2024-12-17 09:55 IRIS2 lifts off as European Commission and SpaceRISE sign contract in Brussels
2024-12-16 15:51 Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union
2024-12-16 10:47 Rosen Law Firm Urges Sun Communities, Inc. (NYSE: SUI) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights
2024-12-16 10:42 Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Business Wire Weibo

Industries

Latest Releases